At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 138 enrolled
Drug / intervention
Nivolumab +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
An Open-Label, Randomized, Phase 2 Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma
In Brief
A Phase 2 clinical trial evaluating Nivolumab and Ipilimumab for Advanced or Metastatic Melanoma. Completed, enrolled 138 participants across 11 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and efficacy of a sequential combination therapy of Nivolumab and Ipilimumab
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced or Metastatic Melanoma
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20132014201520162017201820192020202120222023202420252026
First PostedFeb 2013
Enrollment StartApr 2013
Primary CompletionApr 2015
Study CompletionAug 2020
TodayJul 2026
First PostedFeb 5, 2013
Enrollment StartApr 30, 2013
Primary CompletionApr 3, 2015
Study CompletionAug 12, 2020
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 13.4 years ago
Interventions
Nivolumabbiological
Ipilimumabbiological